Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Cancer Immunol Immunother ; 60(8): 1127-35, 2011 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-21479639

RESUMO

Although cancer immunology has made vigorous progress over the last decade, its future remains uncertain. Tumors have clearly proved subject to immune surveillance, leading to antigenic editing, and means of activating both T and B arms of the immune system have been devised. Therapeutic vaccination and monoclonal antibody therapy have so far proved disappointing, because tumors prove adept at evasion from immune control. Dual targeting could well counteract evasion, provided that the two targets are independent and are attacked simultaneously. This stage has nearly but not quite been reached in several forms of immunotherapy, particularly of B-cell cancers, although such treatment also carries hazards.


Assuntos
Linfócitos B/imunologia , Vacinas Anticâncer , Imunoterapia , Linfócitos T/imunologia , Evasão Tumoral , Animais , Antígenos de Neoplasias/imunologia , Humanos , Epitopos Imunodominantes/imunologia , Vigilância Imunológica , Terapia de Alvo Molecular , Neoplasias
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA